Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety surveillance of Tglobulin 25 in adult kidney transplant candidates
IRCT20201230049888N1Phase 4Completed
- Sponsor
- Kawsar Biotech
- Start
- Nov 2022
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of antithymocyte globulin in kidney failure, sponsored by Kawsar Biotech. Primary endpoint: Delayed graft function. Started Nov 2022; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
kidney failure
Beyond the preview
Go deeper on IRCT20201230049888N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201230049888N1.